This is the first stage in what will be a very short time when a Permanent IND# is received from the FDA to study Blue green algae in HIV+virologically suppressed patients.
There is more and more evidence that 1 or 2 or 3 antiretrovial drugs will not cure HIV infection. That is because the antiretroviral drugs do not stop immune activation caused by HIV infection. What is going to be needed is either gene therapy or antiretroviral drugs plus a supplement like stem cells. Blue green algae is the only oral supplement that releases adult bone marrow stem cells into the circulation by 20-30% after oral ingestion. The increased number of circulating stem cells plus the effect of the cytokine suppressant activity of the algae might be enough to eradicate the virus when coupled with an antiretroviral drug; The algae blocks the uptake of the virus in the gut, increases the life span of memory T-cells, the main reservoir of HIV, and is the most powerful immune enhancer in the body. Stem cells direct the NK cells and also cellular and humoral immunity. We have a phase 2 study ready for implementation and a medical group that wants to do the study with us. Following the markers of immune activation, like D-Dimer, CRP, LPS, viral load and CD cell parameters, plus maybe the most important marker of immune activation, pro-viral DNA, will determine the success or failure of the study.
The Peter Schick Foundation has developed a protocol for LDL cholesterol.
In a pilot study of an HIV infected patient, the data showed a 50% reduction in LDL cholesterol in this patient after 6 months of treatment with blue green algae. The patient did not have abnormally high LDL levels from the start.The foundation is interested in studying LDL cholesterol. A protocol ha been developed to study Blue Algae in people who have an elevated LDL cholesterol. We are looking for a 30 to 40% reduction in LDL cholesterol as significant. Since there are no side effects to Blue green algae, this could lead to the elimination of a lot of anti lipid lowering pharmaceutical drugs. Blue green algae is cheaper, and has fewer side effects than the pharmaceutical drugs available for lowering LDL cholesterol. This protocol fits very well into an already finished protocol dealing with post-coronary bypass patients in rehabilitation. LDL cholesterol is the major contributor to heart disease and stroke. The protocol when implemented should be completed in 6 months.
Two new additions to the Peter Schick Foundation personnel
Two new people will shortly be joining the Peter Schick Foundation. Dr. Michael Hamrell, who has worked as a regulator at the FDA, and both a regulator and a researcher at the NIH, will join the foundation. He will be the director of Basic benchmark research, something he has done in the past. He will also help in the writing and devising of new protocols for the foundation, and will assist the foundation in getting its protocols thru the FDA, as he does in his consulting firm which he runs. Cindy Sopko CPA and life coach will be joining the foundation shortly in a part time position. She will participate in the final stages of the business plan which already has been developed by Michael Fidler and Peter Schick. She will also take part in presentations made to key personnel both in the scientific and fundraising arena. Cindy is an excellent writer and will also participate in newsletters, and messages posted on our web sites.
To see these 2 very important protocols implemented and completed we ask for a donation from you. You can say that you made a difference in some of the major diseases of our time.
To donate you can send a check or money order to The Peter Schick Foundation, 1223 Wilshire Blvd, #1007, Santa Monica California, 90403. Or you can donate on line on either of our two web sites www.schickfoundation.org, or www.schickresearch.com.
Posts
No comments:
Post a Comment